GlassScriptPhysician profile
Charles Robert Bosshardt
NPI 1013215078
$3,379.38
in general payments reported to CMS, 2019-2025
20 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $73.37 · 2021: $117 · 2022: $778 · 2023: $926 · 2024: $601 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113 · Education: $85.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,112.87 |
| Education | $85.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,936.08 | 2020-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $244.62 | 2020-2025 | Xifaxan |
| Enterra Medical, INC. | $163.06 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $140.09 | 2019-2023 | Rebyota |
| Pfizer INC. | $137.28 | 2019-2025 | |
| Janssen Biotech, INC. | $127.24 | 2019-2025 | Tremfya |
| Boston Scientific Corporation | $122.36 | 2021-2025 | Spyglass, Speedband Superview Super 7 |
| Ucb, INC. | $115.27 | 2019-2020 | |
| Braintree Laboratories, INC. | $106.53 | 2022-2024 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $56.06 | 2022-2023 | Dupixent |
| Ardelyx, INC. | $46.22 | 2022-2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $28.35 | 2024 | Dificid |
| Celltrion USA INC. | $26.33 | 2025 | Vegzelma |
| Lilly USA, LLC | $23.68 | 2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $21.13 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $20.64 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.24 | 2024 | Voquezna |
| Capsovision, INC. | $17.53 | 2025 | Capsocam Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.45 | 2024 | Cyltezo |
| Novo Nordisk INC | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Bosshardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.